EVOLUTION OF SCREENING FOR PROSTATE CANCER

Early diagnostic algorithms for prostate cancer has been dramatically changed
for the last 20 years: from massive screening to individual risk-adapted strategy for
well-informed patients in high risk group with estimated life expectancy 10–15 years.
Utilization of modern PSA isoforms, new biological markers and mpMRI help to
avoid unnecessary biopsies, overdiagnosis of clinically insignificant PCa and adverse
outcomes of unreasonable treatment.